Fred Hutch Cancer Center Senior Vice President and Director of the Clinical Research Division Sara Hurvitz, MD, recently received the inaugural Smith Family Endowed Chair in Women’s Health.
First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.
Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.
The mechanisms underlying synergy between checkpoint blockade and anti-angiogenic therapy remain elusive. In this issue of Cancer Cell, Guo et al. analyze hepatocellular carcinoma patients treated…
High-grade disease was associated with worse survival outcomes in Black patients with uterine carcinoma.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.
R. Tyler Hillman, MD, PhD, discusses ways of identifying new drug therapy candidates in patients with adult-type granulosa cell tumor of the ovary.
Nature Reviews Cancer – In this Review, Suvac et al. discuss how intratumoural hypoxia is a driving force in tumour evolution, alongside driver gene mutations,…
Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.
The phase 2b REZILIENT1 trial of zipalertinib in EGFR+ non–small cell lung cancer met its overall response rate primary end point with a consistent safety…
